The purpose of this research study is to collect different types of samples (such as stool, swabs, urine) to form a biorepository. This repository will provide valuable samples from people with and without IBD so that investigators can learn more about the cause of IBD, and different therapies that could be used to treat it. These samples will be used for future gastrointestinal research. Because technology and scientific understanding may advance quickly, it is not yet known what specific studies the samples may be used for.

CAPTURE Inflammatory Bowel Disease (IBD) is a multi-center, longitudinal study designed with the goal of advancing precision medicine in pediatric IBD. Participants in CAPTURE IBD will continue to receive their usual care at the Children's Hospital of Philadelphia. The study team will ask participants to give blood, stool, and tissue samples at the same time as scheduled IBD clinical visits, endoscopy, or bowel surgery visits. Additionally, participants will be asked to complete electronic surveys at scheduled clinic visits, including any scheduled endoscopy or bowel surgery visits. The study will use the biospecimens and health data as a research resource that can help scientists to answer questions like:

• Can we help guide the selection of the most effective IBD therapies for pediatric and young adult populations?
• Can we help identify new treatments for pediatric patients who are not responding to current available therapies?
• Can we advance our understanding of who are the best candidates for surgery in pediatric Crohn's disease and the best treatment approaches after surgery?

CAPTURE IBD will enroll 3,000 patients, ages 4-21 years old, who have an established or suspected diagnosis of IBD at 12 sites across the United States.

The study aims to understand which genes cause IBD and expand on what is known about how IBD affects those with African ancestry.

Patients are being recruited within the first two years of diagnosis at their scheduled infusion visits.

Participation in the study will last up to five years and includes an annual collection of blood, stool, and biopsy samples, and a one-time saliva sample at the first visit.

All study visits will align with clinically indicated visits already scheduled, and biopsy collection will only occur at scopes that are part of the patient's clinical care.

This study is being done in collaboration with hospitals around the country, and is headed by Emory University in Atlanta, Georgia. Participants will be compensated for their time and effort, upon completion of each visit.

The purpose of this study is to help understand how well new IBD medications work, obtain safety information, and understand patient's quality of life while on the medications.

The goals of this research study are to learn more about acute recurrent and chronic pancreatitis in order to better understand the disease in the hopes of enhancing future treatment options. If you and your child agree to participate you will each be asked to: meet with the study team at your annual check-up, complete questionnaires about medical history, family history, and quality of life, agree to a one-time blood or saliva sample collection. All participants will be compensated for their time and effort. If you would be interested in participating, please contact study coordinator Lucia Sanchez by phone at 267-426-8411, or email at sanchezlc@email.chop.edu.

The goal of this study is to find out if we can develop a digital health approach that can increase sleep duration and improve growth outcomes in children.

The purpose of this research study is to help us understand how well tofacitinib works as a treatment for ulcerative colitis or indeterminate colitis in pediatric patients. We are looking to enroll, males or females ages 6 to 21 years old with a diagnosis of ulcerative colitis or indeterminate colitis who have started tofacitinib therapy prescribed by their primary gastroenterologist within the past 2 weeks or will be starting tofafacitinib within 1 month.

Use of elexacaftor-texacaftor-ivacaftor ("ETI"), also known as Trikafta, is associated with weight gain in most people with cystic fibrosis (CF) who take this medication. However, some people gain more or less weight than is expected, and this can be either beneficial or problematic based on the individual's starting weight. The goal of this study is to compare factors between children and young adults with CF who have either had robust or minimal weight gain after one year of treatment with ETI.This observational study requires one study visit to CHOP that will last approximately 6 hours.